Understanding Preterm Birth in Pregnancies Complicated by Nonimmune Hydrops Fetalis
- PMID: 36603834
- PMCID: PMC10330491
- DOI: 10.1055/a-2008-2495
Understanding Preterm Birth in Pregnancies Complicated by Nonimmune Hydrops Fetalis
Abstract
Objective: Nonimmune hydrops fetalis (NIHF) is associated with poor perinatal outcomes including preterm birth (PTB). However, the frequency and causes of PTB in this population are not well understood. We hypothesized that NIHF frequently results in PTB due to medically indicated delivery for fetal distress.
Study design: This was a secondary analysis of a prospectively enrolled cohort of pregnancies with NIHF that underwent exome sequencing if standard testing was nondiagnostic. The primary outcome was frequency of PTB at <37 weeks' gestation. Secondary outcomes were reasons for PTB, fetal predictors of PTB, and frequency of neonatal death following PTB.
Results: Fifty-six cases were included, with a median gestational age at delivery of 32.8 weeks (interquartile range [IQR]: 30.3-35.0). Overall, 86% (48/56) were delivered preterm. Among 48 PTBs, 18 (38%) were spontaneous, 9 (19%) were medically indicated for maternal indications (primarily preeclampsia), and 21 (44%) were medically indicated for fetal indications (nonreassuring antenatal testing or worsening effusions). Neither fetal genetic diagnosis nor polyhydramnios was associated with PTB.
Conclusion: More than four-fifths of pregnancies with NIHF result in PTB, often due to nonreassuring fetal status. These data are informative for counseling patients and for developing strategies to reduce PTB in pregnancies with NIHF.
Key points: · Pregnancies complicated by nonimmune hydrops fetalis often result in preterm birth.. · Preterm birth in these cases is most often medically indicated for fetal benefit.. · Fetal genetic conditions and polyhydramnios may be associated with preterm birth in cases of NIHF..
Thieme. All rights reserved.
Conflict of interest statement
None declared.
Figures
References
-
- Sparks TN, Lianoglou BR, Adami RR, et al.; University of California Fetal-Maternal Consortium; University of California, San Francisco Center for Maternal-Fetal Precision Medicine Exome sequencing for prenatal diagnosis in nonimmune hydrops fetalis. N Engl J Med 2020;383(18):1746–1756 - PMC - PubMed
-
- Norton ME, Chauhan SP, Dashe JS. Society for Maternal-Fetal Medicine (SMFM)Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis. Am J Obstet Gynecol 2015;212(02):127–139 - PubMed
-
- Steurer MA, Peyvandi S, Baer RJ, et al. Epidemiology of live born infants with nonimmune hydrops fetalis — insights from a population-based dataset. J Pediatr 2017;187:182.e3–188.e3 - PubMed
-
- Abrams ME, Meredith KS, Kinnard P, Clark RH. Hydrops fetalis: a retrospective review of cases reported to a large national database and identification of risk factors associated with death. Pediatrics 2007;120(01):84–89 - PubMed
